Stimcell Energetics Inc.

Overview

Compare with ALR Technologies SG Ltd., enVVeno Medical Corp or Odyssey Health, Inc., or pick any stock.

• TickerSTME on OTC¹
• IndustrySurgical & Medical Instruments & Apparatus¹
• HeadquartersVancouver, Canada¹
• Incorporated inNV³
• Business address820 - 1130 Pender Street, West, Vancouver, A1 V6E 4A4³
• Filer categoryNon-accelerated filer, Smaller reporting company³
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Stimcell Energetics Inc. was incorporated under the laws of the State of Nevada on March 19, 2010. On April 26, 2016, the Company formed its wholly owned subsidiary, Cell MedX (Canada) Corp., (the “Subsidiary”) under the laws of the Province of British Columbia.⁴ From its latest annual report

Corporate structure

Stimcell Energetics Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Stimcell Energetics Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Properties, in its own words

The Company’s principal executive office is located at 555 - 1130 West Pender Street, Vancouver, BC V6E 4A4, Canada, which is also the principal office of the Company’s Subsidiary. The Company also maintains a virtual office at 123 W. Nye Ln, Suite 446, Carson City, NV 89706, USA. In addition to these offices, the Company does not currently maintain any other facilities and does not anticipate the need for additional facilities at any time in the foreseeable future.

Item 2 of the 10-K filed Aug 31, 2026.⁴

Leadership

Who has led Stimcell Energetics Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerDavid Jeffs Jan 9, 2024 to Jan 10, 2024¹⁴
• Chief executive officerDwayne Yaretz May 18, 2022 to May 18, 2022¹⁵
• Chief executive officerTerrance George Owen Dec 11, 2017 to Dec 11, 2017¹⁶
• Chief executive officerFrank McEnulty Mar 10, 2014 to Sep 1, 2020¹⁷
• PresidentFrank McEnulty Aug 6, 2015 to Sep 1, 2020¹⁸
• Chief financial officerFrank McEnulty Mar 10, 2014 to Mar 10, 2014¹⁷
• Chief financial officerYanika S. Silina Nov 26, 2014 to Oct 18, 2017¹⁹
• Chief operating officerJoao Dacosta Jun 11, 2020 to Jun 11, 2020²⁰

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerYana Silina named May 9, 2025²⁸
• DirectorJoao (John) Da Costa named Mar 26, 2024 to May 9, 2025²⁸

Former names

• Cell MedX Corp.Oct 17, 2014 to Oct 15, 2024³
• Sports Asylum, Inc.Apr 14, 2014 to Oct 9, 2014³
• Plandel Resources, Inc.Jul 13, 2010 to Mar 24, 2014³

Timeline

1. Sep 8, 20268-K Entered a material agreement; Regulation FD disclosure²⁹
2. Mar 20, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure³⁰
3. Dec 2, 20258-K Regulation FD disclosure³¹
4. Mar 28, 20258-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure³²
5. Feb 27, 20258-K Regulation FD disclosure³³
6. Jan 8, 20258-K Regulation FD disclosure³⁴
7. Nov 5, 20248-K Bylaws or fiscal year changed; Other events³⁵
8. Apr 4, 20248-K Unregistered sale of shares; Bylaws or fiscal year changed³⁶
9. Mar 19, 20248-K Entered a material agreement; Unregistered sale of shares³⁷
10. Feb 28, 20248-K Executive or director change³⁸
11. Jan 9, 2024New chief executive David Jeffs becomes CEO¹⁴
12. Dec 19, 20238-K Unregistered sale of shares; Change in control; Executive or director change³⁹
13. Nov 27, 20238-K Other events⁴⁰
14. May 18, 2022New chief executive Dwayne Yaretz becomes CEO¹⁵
15. Dec 11, 2017New chief executive Terrance George Owen becomes CEO¹⁶
16. Mar 10, 2014New chief executive Frank McEnulty becomes CEO¹⁷

Filings

67 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 15 major events, 19 insider forms, 1 large holders, 2 private raises, 9 other. The latest 20:

1. Oct 14, 202610-Q QUARTERLY REPORT EDGAR
2. Sep 8, 20268-K CURRENT REPORT EDGAR
3. Aug 31, 202610-K ANNUAL REPORT EDGAR
4. Apr 10, 202610-Q QUARTERLY REPORT EDGAR
5. Mar 20, 20268-K CURRENT REPORT EDGAR
6. Jan 15, 202610-Q QUARTERLY REPORT EDGAR
7. Jan 15, 2026NT 10-Q FORM 12B-25 EDGAR
8. Dec 19, 20254 PRIMARY DOCUMENT EDGAR
9. Dec 2, 20258-K CURRENT REPORT EDGAR
10. Oct 14, 202510-Q QUARTERLY REPORT EDGAR
11. Sep 2, 202510-K STIMCELL ENERGETICS INC. - FORM 10-K SEC FILING EDGAR
12. Sep 2, 2025NT 10-K FORM 12B-25 EDGAR
13. May 9, 2025D EDGAR
14. Apr 14, 202510-Q STIMCELL ENERGETICS INC. - FORM 10-Q SEC FILING EDGAR
15. Mar 28, 20258-K STIMCELL ENERGETICS INC. - FORM 8-K SEC FILING EDGAR
16. Mar 25, 20254 PRIMARY DOCUMENT EDGAR
17. Feb 27, 20258-K STIMCELL ENERGETICS INC. - FORM 8-K SEC FILING EDGAR
18. Feb 25, 20254 PRIMARY DOCUMENT EDGAR
19. Jan 14, 202510-Q STIMCELL ENERGETICS INC. - FORM 10-Q SEC FILING EDGAR
20. Jan 8, 20258-K STIMCELL ENERGETICS INC. - FORM 8-K SEC FILING EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

14 open-market trades by officers, directors and large owners since October 2021: 4 buys and 10 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Amir VahabzadehSC 13D, 1 filing Sep 7, 2023⁴¹

Money raised

Private offerings the company reported to the SEC on Form D.

1. Apr 10, 2025Raised $15,000 in a private offering of equity Form D: 1 investor so far Form D
2. Mar 11, 2024Raised $45,000 in a private offering of equity Form D: $120,000 offered in all Form D

SEC filer profile

How Stimcell Energetics Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARStimcell Energetics Inc.¹
• CIK0001493712
• Employer ID (EIN)38-3939625⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inNevada⁴
• Fiscal year endsMay 31¹
• Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address820 - 1130 Pender Street, West, Vancouver, A1 V6E 4A4¹
• Phone(844) 238-2692¹
• Shares outstanding21,141,272 as of Oct 14, 2026¹³
• Public float$2.4M as of ⁴
• AuditorDMCL LLP, Vancouver, Canada PCAOB ID 1173; no auditor attestation of internal control over financial reporting⁴
• On EDGAR sinceJul 13, 2010¹
• Filings273 in all: 4 (95), 10-Q (46), 8-K (43), 10-K (16), 3 (13), NT 10-K (8), D (7), 10-Q/A (5)¹
  All 25 form types

  424B3 (5), CORRESP (4), NT 10-Q (4), SC 13D (4), UPLOAD (4), S-1/A (3), 10-K/A (2), 144 (2), EFFECT (2), S-1 (2), SC 13D/A (2), 4/A (1), 424B1 (1), 8-A12G (1), DEF 14C (1), PRE 14C (1), SC 14F1 (1)

• Latest filingsAnnual report (10-K) Aug 31, 2026
  Quarterly report (10-Q) Oct 14, 2026
  Latest 8-K (8-K) Sep 8, 2026

Risk factors and legal proceedings

The risks Stimcell Energetics Inc. names in Item 1A of its 10-K filed Aug 31, 2026: 19 risks under these headings, as written.⁴

• Risks Associated with the Company and Industry it Operates in
• The Company operates in a highly competitive market. The Company faces competition from large, well established medical device manufacturers and pharmaceutical companies in the market for treatment of pain and management of diabetes and related ailments. Many of these companies are very well accepted by health practitioners and have significant resources, and the Company may not be able to compete effectively.
• The Company is subject to numerous governmental regulations which can increase its costs of developing the eBalance® Technology and products based on this technology.
• Changes in the health care regulatory environment may adversely affect the Company’s business.
• Inability to protect and enforce the Company’s intellectual property rights could adversely affect its financial results.
• Competitors’ intellectual property may prevent the Company from selling its products or have a material adverse effect on its future profitability and financial condition.
• The Company’s research and development efforts may not result in the development of commercially successful products based on its eBalance® Technology, which may hinder its profitability and future growth.
• Even if the Company successfully develops marketable products or commercially develop its current Technology, it may be quickly rendered obsolete by changing customer preferences, changing industry standards, or competitors’ innovations.
• New products and technological advances by the Company’s competitors may negatively affect its results of operations.
• Significant safety concerns could arise for the Company’s products, which could have a material adverse effect on its revenues and financial condition.
• Inability to attract and maintain key personnel may cause the Company’s business to fail.
• The Company lacks operating history and to date has generated only minimal revenues. If the Company cannot increase its revenue to start generating profits, its investors may lose their entire investment.

Legal proceedings

The Company is not a party to any pending legal proceedings and, to the best of its knowledge, none of its properties or assets are the subject of any pending legal proceedings.

The opening of Item 3, Legal Proceedings.⁴